Jan Budczies

Jun 12, 2024 | nature.com | Jan Budczies |Eva Romanovsky |Olaf Neumann |Thorsten Stiewe |Daniel Kazdal |Petros Christopoulos

AbstractPredictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information. The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations.

Oct 20, 2023 | nature.com | Michael Menzel |Patrick Metzger |Peter Horak |Melanie Boerries |Markus Ball |Olaf Neumann | +11 more

AbstractA growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire coding sequence, segmentation-based detection of copy number alterations (CNAs), and accurate determination of complex biomarkers including tumor mutational burden (TMB), homologous recombination repair deficiency (HRD), and microsatellite instability (MSI).

Oct 20, 2023 | nature.com | Michael Menzel |Patrick Metzger |Peter Horak |Melanie Boerries |Markus Ball |Olaf Neumann | +11 more

AbstractA growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire coding sequence, segmentation-based detection of copy number alterations (CNAs), and accurate determination of complex biomarkers including tumor mutational burden (TMB), homologous recombination repair deficiency (HRD), and microsatellite instability (MSI).